Avectas Limited

Michael Maguire, CEO

April 11 | 10:30am | Salone dei Cavalieri, Section 2

Dublin, Ireland


Avectas has developed Solupore, a ground-breaking non-viral cell engineering platform for next-gen cell therapies. It excels at yielding cells with high viability, functionality, and potent cytotoxicity for patient dosing, after complex gene editing. Solupore gives therapeutic developers new manufacturing options including 



By using this website you agree to accept our Privacy Policy and Terms & Conditions